Literature DB >> 29374275

Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?

Youmna Ghaleb1,2,3, Sandy Elbitar1,2,3, Petra El Khoury1,3, Eric Bruckert4, Valérie Carreau4, Alain Carrié5, Philippe Moulin6, Mathilde Di-Filippo7, Sybil Charriere6, Harout Iliozer6, Michel Farnier8, Gérald Luc9, Jean-Pierre Rabès10,11, Catherine Boileau1,2,12, Marianne Abifadel1,3, Mathilde Varret13,14.   

Abstract

Familial hypercholesterolemia (FH) is caused by mutations in LDLR (low-density lipoprotein receptor), APOB (apolipoprotein B), PCSK9 (proprotein convertase subtilisin/kexin type 9), or APOE (apolipoprotein E) genes in approximately 80% of the cases. Polygenic forms of hypercholesterolemia may be present among patients clinically diagnosed with FH but with no identified mutation (FH mutation-negative (FH/M-)). To address whether polygenic forms may explain phenocopies in FH families, we calculated a 6-single-nucleotide polymorphism (SNP) genetic risk score (GRS) in all members from five French FH families where a mutation was identified (FH/M+) as well as some phenocopies (FH/M-). In two families, three FH/M- patients present a high GRS suggesting a polygenic hypercholesterolemia for these phenocopies. However, a high GRS is also observed in nine FH/M+ patients and in four unaffected relatives from three families. These observations indicate that the GRS does not seem to be a good diagnostic tool at the individual level. Nevertheless, the GRS seems to be a contributor of the severity of hypercholesterolemia since patients who cumulate a mutation and a high GRS exhibit higher low-density lipoprotein cholesterol levels when compared to patients with only FH (p = 0.054) or only polygenic hypercholesterolemia (p = 0.0039). In conclusion, the GRS can be used as a marker of the severity of hypercholesterolemia but does not seem to be a reliable tool to distinguish phenocopies within FH families.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29374275      PMCID: PMC5891487          DOI: 10.1038/s41431-017-0078-y

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  24 in total

1.  Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort.

Authors:  G Siest; S Visvikis; B Herbeth; R Gueguen; M Vincent-Viry; C Sass; B Beaud; E Lecomte; J Steinmetz; J Locuty; P Chevrier
Journal:  Clin Chem Lab Med       Date:  1998-01       Impact factor: 3.694

2.  Exome sequencing in suspected monogenic dyslipidemias.

Authors:  Nathan O Stitziel; Gina M Peloso; Marianne Abifadel; Angelo B Cefalu; Sigrid Fouchier; M Mahdi Motazacker; Hayato Tada; Daniel B Larach; Zuhier Awan; Jorge F Haller; Clive R Pullinger; Mathilde Varret; Jean-Pierre Rabès; Davide Noto; Patrizia Tarugi; Masa-Aki Kawashiri; Atsushi Nohara; Masakazu Yamagishi; Marjorie Risman; Rahul Deo; Isabelle Ruel; Jay Shendure; Deborah A Nickerson; James G Wilson; Stephen S Rich; Namrata Gupta; Deborah N Farlow; Benjamin M Neale; Mark J Daly; John P Kane; Mason W Freeman; Jacques Genest; Daniel J Rader; Hiroshi Mabuchi; John J P Kastelein; G Kees Hovingh; Maurizio R Averna; Stacey Gabriel; Catherine Boileau; Sekar Kathiresan
Journal:  Circ Cardiovasc Genet       Date:  2015-01-27

Review 3.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

4.  Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.

Authors:  Roeland Huijgen; Barbara Sjouke; Kelly Vis; Janine S E de Randamie; Joep C Defesche; John J P Kastelein; G Kees Hovingh; Sigrid W Fouchier
Journal:  Hum Mutat       Date:  2011-12-22       Impact factor: 4.878

5.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 6.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

Authors:  T L Innerarity; R W Mahley; K H Weisgraber; T P Bersot; R M Krauss; G L Vega; S M Grundy; W Friedl; J Davignon; B J McCarthy
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

Review 7.  Familial Hypercholesterolemia: Advances in Recognition and Therapy.

Authors:  Jacqueline L Cartier; Anne Carol Goldberg
Journal:  Prog Cardiovasc Dis       Date:  2016-07-29       Impact factor: 8.194

8.  Molecular spectrum of autosomal dominant hypercholesterolemia in France.

Authors:  Marie Marduel; Alain Carrié; Agnes Sassolas; Martine Devillers; Valérie Carreau; Mathilde Di Filippo; Danièle Erlich; Marianne Abifadel; Alice Marques-Pinheiro; Arnold Munnich; Claudine Junien; Catherine Boileau; Mathilde Varret; Jean-Pierre Rabès
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

9.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

10.  Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.

Authors:  Marta Futema; Vincent Plagnol; KaWah Li; Ros A Whittall; H Andrew W Neil; Mary Seed; Stefano Bertolini; Sebastiano Calandra; Olivier S Descamps; Colin A Graham; Robert A Hegele; Fredrik Karpe; Ronen Durst; Eran Leitersdorf; Nicholas Lench; Devaki R Nair; Handrean Soran; Frank M Van Bockxmeer; Steve E Humphries
Journal:  J Med Genet       Date:  2014-07-01       Impact factor: 6.318

View more
  8 in total

Review 1.  The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats.

Authors:  Amanda J Hooper; John R Burnett; Damon A Bell; Gerald F Watts
Journal:  Curr Atheroscler Rep       Date:  2018-05-19       Impact factor: 5.113

Review 2.  Molecular diagnosis methods in familial hypercholesterolemia.

Authors:  Valeriu Moldovan; Claudia Banescu; Minodora Dobreanu
Journal:  Anatol J Cardiol       Date:  2020-02       Impact factor: 1.596

Review 3.  Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor.

Authors:  Estíbaliz Jarauta; Ana Ma Bea-Sanz; Victoria Marco-Benedi; Itziar Lamiquiz-Moneo
Journal:  Front Genet       Date:  2020-12-03       Impact factor: 4.599

4.  Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank.

Authors:  Mengyu Li; Jie V Zhao; Man Ki Kwok; C Mary Schooling
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

Review 5.  Artificial Intelligence and Cardiovascular Genetics.

Authors:  Chayakrit Krittanawong; Kipp W Johnson; Edward Choi; Scott Kaplin; Eric Venner; Mullai Murugan; Zhen Wang; Benjamin S Glicksberg; Christopher I Amos; Michael C Schatz; W H Wilson Tang
Journal:  Life (Basel)       Date:  2022-02-14

6.  Screening of common genetic variants in the APOB gene related to familial hypercholesterolemia in a Saudi population: A case-control study.

Authors:  Mohammed Ali Batais; Turky H Almigbal; Noor Ahmad Shaik; Fawaziah Khalaf Alharbi; Khalid Khalaf Alharbi; Imran Ali Khan
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

7.  Targeted Genetic Analysis in a Chinese Cohort of 208 Patients Related to Familial Hypercholesterolemia.

Authors:  Hao Wang; Hang Yang; Zhaohui Liu; Kai Cui; Yinhui Zhang; Yujing Zhang; Kun Zhao; Kunlun Yin; Wenke Li; Zhou Zhou
Journal:  J Atheroscler Thromb       Date:  2020-08-06       Impact factor: 4.928

8.  Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia.

Authors:  Youmna Ghaleb; Sandy Elbitar; Anne Philippi; Petra El Khoury; Yara Azar; Miangaly Andrianirina; Alexia Loste; Yara Abou-Khalil; Gaël Nicolas; Marie Le Borgne; Philippe Moulin; Mathilde Di-Filippo; Sybil Charrière; Michel Farnier; Cécile Yelnick; Valérie Carreau; Jean Ferrières; Jean-Michel Lecerf; Alexa Derksen; Geneviève Bernard; Marie-Soleil Gauthier; Benoit Coulombe; Dieter Lütjohann; Bertrand Fin; Anne Boland; Robert Olaso; Jean-François Deleuze; Jean-Pierre Rabès; Catherine Boileau; Marianne Abifadel; Mathilde Varret
Journal:  Metabolites       Date:  2022-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.